Amgen vs Bristol Myers Squibb
AMGN and BMY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMGN and BMY compare
Amgen is the larger company, worth 2.0 times as much as Bristol Myers Squibb ($248B against $125B).
On earnings, Bristol Myers Squibb is cheaper: it trades at 13.6× trailing earnings, against 26.5× for Amgen.
Amgen grew revenue faster over the last twelve months (8.2% versus 4.2% for Bristol Myers Squibb).
Amgen keeps more of each dollar of sales as profit, with a net margin of 24.1% compared with 18.5% at Bristol Myers Squibb.
Both pay dividends: Amgen yields 2.2% and Bristol Myers Squibb 4.1%.
Amgen scores higher on the StockData Score (17 against 14 for Bristol Myers Squibb), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMGN | BMY |
|---|---|---|
| Size and price | ||
| Market cap | $248B | $125B |
| Share price | $457.93 | $61.35 |
| Change, 1 year | 36.0% | 31.5% |
| Change, 5 years | 128% | 8.5% |
| Beta (5Y) | 0.32 | 0.11 |
| Employees | 32K | 33K |
| StockData Score | ||
| Total score | 17 (better) | 14 |
| Valuation score | 0 | 4 (better) |
| Growth score | 5 (better) | 0 |
| Performance score | 6 (better) | 3 |
| Health score | 2 | 2 |
| Dividend score | 4 | 5 (better) |
| Valuation | ||
| P/E | 26.5× | 13.6× (better) |
| P/S | 6.4× | 2.5× (better) |
| P/B | 17.3× | 5.4× (better) |
| EV/EBITDA | 18.8× | 9.9× (better) |
| P/FCF | 25.8× | 13.5× (better) |
| PEG | 4.81 | 2.49 (better) |
| FCF yield | 3.9% | 7.4% (better) |
| Fair value | $364.40 | $87.76 |
| Margin of safety | −25.7% | 30.1% (better) |
| Growth | ||
| Revenue growth (TTM) | 8.2% (better) | 4.2% |
| Revenue growth, 5Y average | 7.6% (better) | 2.5% |
| Net income growth (TTM) | 34.1% | 53.1% (better) |
| EPS growth (TTM) | 33.3% | 52.4% (better) |
| EPS growth, 5Y average | 2.9% | – |
| Profitability | ||
| Gross margin | 70.9% (better) | 69.2% |
| Operating margin | 32.4% | – |
| Net margin | 24.1% (better) | 18.5% |
| FCF margin | 24.6% (better) | 18.6% |
| Return on equity | 78.4% (better) | 44.1% |
| Return on invested capital | 19.5% | – |
| Financial health | ||
| Debt / equity | 3.76 | 1.83 (better) |
| Net debt / EBITDA | 2.67 | 1.92 (better) |
| Interest coverage | 4.8× | – |
| Current ratio | 1.48 | 1.59 (better) |
| Altman Z-score | 2.51 (better) | 2.20 |
| Piotroski F-score | 7 | 8 (better) |
| Dividends and buybacks | ||
| Dividend yield | 2.2% | 4.1% (better) |
| Payout ratio | 57.1% | 55.4% |
| Years of dividend growth | 9 | 16 (better) |
| Dividend growth, 5Y average | 8.0% (better) | 6.2% |
| Shareholder yield | 2.2% | 4.1% (better) |
| Ownership | ||
| Held by institutions | 82.7% | 81.9% |
| Held by insiders | 0.21% | 0.06% |
| Insider net buying, 12 months | −$25.7M | −$2.5M (better) |
| Superinvestors holding | – | 2 |
| Short interest, % of float | 2.3% | 2.3% |
Go deeper
- AMGN stock overview
- AMGN income statement
- AMGN valuation and score
- BMY stock overview
- BMY income statement
- BMY valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.